HC Wainwright Has Negative Outlook of EYPT FY2024 Earnings

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Stock analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for EyePoint Pharmaceuticals in a report issued on Monday, November 11th. HC Wainwright analyst Y. Chen now expects that the company will earn ($2.15) per share for the year, down from their previous forecast of ($2.09). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.20) per share. HC Wainwright also issued estimates for EyePoint Pharmaceuticals’ Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.59) EPS and FY2025 earnings at ($2.06) EPS.

A number of other analysts have also issued reports on EYPT. Robert W. Baird dropped their price objective on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a research note on Monday. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a “sell” rating in a report on Saturday, September 21st. Jefferies Financial Group began coverage on EyePoint Pharmaceuticals in a research note on Wednesday, August 28th. They set a “buy” rating and a $15.00 target price for the company. Chardan Capital boosted their price target on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Finally, Scotiabank assumed coverage on EyePoint Pharmaceuticals in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 price target for the company. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.00.

EyePoint Pharmaceuticals Stock Performance

EyePoint Pharmaceuticals stock opened at $10.49 on Thursday. The firm has a market capitalization of $561.42 million, a PE ratio of -5.25 and a beta of 1.50. EyePoint Pharmaceuticals has a one year low of $5.86 and a one year high of $30.99. The stock’s 50 day moving average price is $9.71 and its 200 day moving average price is $9.91.

Institutional Trading of EyePoint Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Ameritas Investment Partners Inc. increased its holdings in shares of EyePoint Pharmaceuticals by 44.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,719 shares of the company’s stock valued at $77,000 after acquiring an additional 1,136 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in EyePoint Pharmaceuticals by 68.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock worth $82,000 after purchasing an additional 4,172 shares during the period. Greenwich Wealth Management LLC increased its stake in EyePoint Pharmaceuticals by 8.3% during the third quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company’s stock valued at $93,000 after purchasing an additional 900 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of EyePoint Pharmaceuticals by 271.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company’s stock worth $95,000 after purchasing an additional 7,953 shares during the period. Finally, Cyndeo Wealth Partners LLC bought a new position in shares of EyePoint Pharmaceuticals in the 3rd quarter worth about $100,000. Institutional investors and hedge funds own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.